Advantage Alpha Capital Partners LP Avidity Biosciences, Inc. Transaction History
Advantage Alpha Capital Partners LP
- $419 Million
- Q3 2024
A detailed history of Advantage Alpha Capital Partners LP transactions in Avidity Biosciences, Inc. stock. As of the latest transaction made, Advantage Alpha Capital Partners LP holds 10,248 shares of RNA stock, worth $308,567. This represents 0.11% of its overall portfolio holdings.
Number of Shares
10,248Holding current value
$308,567% of portfolio
0.11%Shares
1 transactions
Others Institutions Holding RNA
# of Institutions
255Shares Held
107MCall Options Held
224KPut Options Held
161K-
Price T Rowe Associates Inc Baltimore, MD10.6MShares$320 Million0.06% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.23MShares$278 Million0.01% of portfolio
-
Black Rock Inc. New York, NY8.62MShares$260 Million0.01% of portfolio
-
Rtw Investments, LP New York, NY8.13MShares$245 Million5.95% of portfolio
-
Wellington Management Group LLP Boston, MA7.03MShares$212 Million0.06% of portfolio
About Avidity Biosciences, Inc.
- Ticker RNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 52,127,000
- Market Cap $1.57B
- Description
- Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic...